<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pharmacology Test  Ii - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
 
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
 
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / NEET PG Test Series Subject Wise / Year 2019 - 20
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">75</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "text": "Which of the following is gametocidal to all the species causing malaria?",
    "choices": [
      {
        "id": 1,
        "text": "Primaquine"
      },
      {
        "id": 2,
        "text": "Chloroquine"
      },
      {
        "id": 3,
        "text": "Quinine"
      },
      {
        "id": 4,
        "text": "None"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Primaquine</strong> is <strong>gametocidal</strong> <strong>to all species</strong> causing malaria. It inhibits transmission of malaria.</p>\n<p>The drugs with clinically important gametocidal activity (against all species) are:</p>\n<ul>\n<li>High activity:\n<ul>\n<li>Artemisinins</li>\n<li>Primaquine</li>\n</ul>\n</li>\n<li>Low to moderate activity:\n<ul>\n<li>Chloroquine</li>\n<li>Quinine</li>\n<li>Atovaquone/proguanil</li>\n</ul>\n</li>\n<li>No activity:\n<ul>\n<li>Mefloquine</li>\n<li>Pyrimethamine</li>\n<li>Sulfadoxine</li>\n<li>Tetracycline</li>\n</ul>\n</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/0735275b88fc4d678851ba62673b565ex1280x1621.JPEG"
    ]
  },
  {
    "text": "Correct pairing of drug and its mechanism of action among the following is?",
    "choices": [
      {
        "id": 1,
        "text": "Cetuximab - Angiogenesis inhibitor"
      },
      {
        "id": 2,
        "text": "Erlotinib \u2013 Human EGFR1 monoclonal Ab"
      },
      {
        "id": 3,
        "text": "Rituximab \u2013 Anti CD20 monoclonal antiboides"
      },
      {
        "id": 4,
        "text": "Trastuzumab \u2013 Human EGFR 1 monoclonal Ab"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Rituximab</strong> is an <strong>anti CD20 monoclonal antibody.</strong></p>\n<ul>\n<li>Rituximab is a chimeric monoclonal antibody that targets the CD20 B-cell antigen. CD20 is found on cells from the pre&ndash;B cell stage through its terminal differentiation to plasma cells and is expressed on <strong>90% of B-cell neoplasms</strong>.</li>\n<li>Monoclonal antibody binding to CD20 generates transmembrane signals that produce <strong>autophosphorylation and activation of serine/tyrosine protein kinases</strong>, induction of <em>c-Myc </em>oncogene expression, and expression of major histocompatibility complex class II molecules.</li>\n<li>Rituximab is approved as a single agent for <strong>relapsed indolent lymphomas</strong> and significantly enhances response and survival in combination with chemotherapy for the initial treatment of<strong> diffuse large B-cell lymphoma(DLBCL)</strong>.</li>\n<li>It remains effective in patients who relapse after initial treatment with rituximab-based combinations.</li>\n<li>Rituximab improves response rates when added to combination chemotherapy for other indolent B-cell non-Hodgkin&rsquo;s lymphomas (NHLs), including CLL, mantle cell lymphoma, Waldenstro\u0308m macroglobulinemia, and marginal zone lymphomas.</li>\n</ul>\n<p class=\"p1\">The <strong>EGFR</strong> belongs to the ErbB family of transmembrane receptor tyrosine kinases also known as ErbB1 or HER1 (human EGFR 1). EGFR is essential for the growth and differentiation of epithelial cells.</p>\n<p class=\"p1\"><strong>Two separate classes of drugs</strong> that target the EGFR pathway are important in the therapy of solid tumors:</p>\n<ol>\n<li class=\"p1\"><strong>Monoclonal antibodies</strong> recognize the extracellular domain of the EGFR, inhibit ligand-induced signaling, and can elicit an immune response.&nbsp;<strong>Cetuximab</strong>&nbsp;is a recombinant, chimeric human/mouse IgG<span class=\"s1\">1 </span>antibody that binds to <strong>EGFR</strong> and prevents ligand-dependent signaling and receptor dimerization, thereby blocking cell growth and survival signals. It is used to treat patients with <strong>metastatic colon cancers and Head and neck squamous cell carcinoma(HNSCC)</strong>.</li>\n<li class=\"p1\"><strong>Protein tyrosine kinase inhibitors</strong>&nbsp;bind to the intracellular kinase domain and inhibit the enzymatic function of an EGFR. Erlotinib is a reversible EGFR tyrosine kinase inhibitor used for advanced <strong>non-small cell lung cancer</strong>(NSCLC) with mutant EGFR and advanced <strong>pancreatic cancer</strong> in combination with gemcitabine.</li>\n</ol>\n<p class=\"p1\"><strong>Trastuzumab</strong> is a humanized IgG1 monoclonal antibody of <strong>HER2</strong>-human epidermal growth factor receptor 2, inhibiting hetero- and homodimerization and signal transduction. It is approved for HER2-overexpressing <strong>breast and gastric cancer.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The drug efavirenz inhibits",
    "choices": [
      {
        "id": 1,
        "text": "HIV protease"
      },
      {
        "id": 2,
        "text": "HIV integrase"
      },
      {
        "id": 3,
        "text": "HIV reverse transcriptase"
      },
      {
        "id": 4,
        "text": "HIV entry into cell"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The drug <strong>efavirenz</strong> <strong>inhibits&nbsp;HIV reverse transcriptase</strong>. It is an NNRTI.</p>\n<p>There are five classes of drugs in combination can be termed antiretro viral therapy (ART), combination antiretroviral therapy (cART) or highly active antiretroviral therapy (HAART).</p>\n<p>Antiretroviral drugs are classified by the phase of the retrovirus life cycle that the drug inhibits.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/55f6f5aafdc94595ab07d959ee58f480x769x673.JPEG"
    ]
  },
  {
    "text": "Which among the following is a motilide?",
    "choices": [
      {
        "id": 1,
        "text": "Erythromycin"
      },
      {
        "id": 2,
        "text": "Ceftriaxone"
      },
      {
        "id": 3,
        "text": "Tetracycline"
      },
      {
        "id": 4,
        "text": "Ciprofloxacin"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>The name \"motilide\" refers to a <strong>motilin-like macrolide</strong>. The effects of motilin can be mimicked by <strong>erythromycin</strong>.</p>\n<p>Erythromycin <strong>induces phase III migrating motor complex.</strong></p>\n<p>It has multiple effects on upper GI motility, increasing lower esophageal pressure and stimulating gastric and small-bowel contractility. However, it has <strong>little or no effect on colonic motility</strong>.</p>\n<p class=\"p1\">Erythromycin is used as a <strong>prokinetic</strong> agent in patients with <strong>diabetic gastroparesis</strong>, where it can improve gastric emptying in the short term.</p>\n<p class=\"p1\">Rapid development of tolerance (~28 days) to erythromycin, possibly by downregulation of the motilin receptor, and antibiotic effects (undesirable in this context) limit the use of this drug as a prokinetic agent.</p>\n<p class=\"p1\">A standard dose of erythromycin for gastric stimulation is <strong>1.5&ndash;3 mg/kg intravenous infusion</strong> every 6 h in a hospital setting or <strong>125 mg orally</strong> every 12 h.</p>\n<p>At doses higher than 3 mg/kg, it can produce a spastic type of contraction in the small bowel, resulting in cramps, impairment of transit, and vomiting.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 48-year-old male patient presented with severe restlessness, palpitations, facial flushing, and sweating. The patient had an episode of dysentery 2 days prior and had been prescribed medication for that. The patient reports taking alcohol 2 hours after his medications. Which of the following drug does not cause similar effects?",
    "choices": [
      {
        "id": 1,
        "text": "Metronidazole"
      },
      {
        "id": 2,
        "text": "Tinidazole"
      },
      {
        "id": 3,
        "text": "Ofloxacin"
      },
      {
        "id": 4,
        "text": "Cefoperazone"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The given clinical scenario of a patient developing symptoms like <strong>restlessness</strong> and <strong>flushing</strong> <strong>after taking alcohol after medication</strong> is suggestive of a <strong>disulfiram-like reaction</strong>. Among the given drugs, <strong>ofloxacin</strong> is <strong>not associated</strong> with a <strong>disulfiram-like reaction</strong>.</p>\n<p>Some important drugs which cause a disulfiram-like reaction are:</p>\n<ul>\n<li><strong>Metronidazole, Tinidazole</strong></li>\n<li>Some cephalosporins<strong>&nbsp;</strong>like <strong>cefoperazone</strong></li>\n<li>1st generation sulfonylureas like tolbutamide</li>\n<li>Procarbazine</li>\n</ul>\n<p>These drugs <strong>inhibit aldehyde dehydrogenase</strong>, similar to disulfiram. When alcohol is combined with these drugs, acetaldehyde accumulates and causes unpleasant symptoms like flushing, sweating, tachycardia, hypotension, nausea, vomiting, dizziness, and headache.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which drug can be used for pain relief in a patient with the following barium swallow?",
    "choices": [
      {
        "id": 1,
        "text": "Paracetamol"
      },
      {
        "id": 2,
        "text": "Tramadol"
      },
      {
        "id": 3,
        "text": "Morphine"
      },
      {
        "id": 4,
        "text": "Sildenafil"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Sildenafil citrate</strong> - PDE 5 inhibitor can be used for pain relief in <strong>diffuse esophageal spasm</strong>.</p>\n<p>The image <strong>depicts Corkscrew / Rosary bead appearance</strong> of the esophagus, characteristically seen in <strong>Diffuse Esophageal Spasm.</strong></p>\n<p>The pathophysiology of the disease, at least in part, involves inadequate Nitric Oxide(NO) synthesis or impaired Degradation of NO.</p>\n<p><strong>Treatment</strong>:</p>\n<p>Initial Therapy: Calcium Channel Blocker - <strong>CCB</strong> (Diltiazem)</p>\n<p>Tri-Cyclic Antidepressants - <strong>TCA</strong> (Imipramine)</p>\n<p>For resistant Cases:NO Donors (<strong>Sildenafil/Nitrates)</strong></p>\n<p><strong>Botulinum Toxin.</strong></p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/df616c8d96b94adca2542967a691f8a6.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "Treatment for the nutritional form of this disease includes:",
    "choices": [
      {
        "id": 1,
        "text": "Joule\u2019s Solution"
      },
      {
        "id": 2,
        "text": "Shohl\u2019s Solution"
      },
      {
        "id": 3,
        "text": "Stoss Therapy"
      },
      {
        "id": 4,
        "text": "Calcium Supplements"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The image shows an X-Ray that is suggestive of<strong> Rickets. </strong>There is <strong>thickening and widening of the growth plate.</strong></p>\n<p><strong>Stoss therapy</strong> is used to treat <strong>nutritional rickets.</strong><br /><br /></p>\n<p>Treatment of <strong>nutritional rickets</strong> is by :</p>\n<p><strong>Stoss therapy</strong> - 3 - 6 lakh international units of Vit D IM or Oral. Alternatively, Daily high dose Vit. D orally - 2000-5000 IU Day, over 4-6 weeks -&gt; followed by 400 IU per day with calcium supplements for 2-4 months.</p>\n<p><strong>Hypophosphatemic Rickets</strong> is treated with Joule&rsquo;s Solution ( Dibasic Sodium Phosphate &amp; Phosphoric Acid).</p>\n<p><strong>Renal Tubular Acidosis</strong> <strong>associated Rickets</strong> is treated with <strong>Shohl&rsquo;s Solution</strong> ( Citric Acid &amp; Sodium Citrate), Bicarbonate and Phosphate supplementation.</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/8fdfb392b7bf40a6a930c7765f899b6e.PNG"
    ],
    "explanation_images": []
  },
  {
    "text": "Which of the following is a 5th generation cephalosporin?",
    "choices": [
      {
        "id": 1,
        "text": "Ceftaroline"
      },
      {
        "id": 2,
        "text": "Cefdinir Pivoxil"
      },
      {
        "id": 3,
        "text": "Cefadroxil"
      },
      {
        "id": 4,
        "text": "Ceftizoxime"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Ceftaroline</strong> is a <strong>fifth-generation cephalosporin</strong>, which exhibits broad-spectrum activity against Gram-positive bacteria, including MRSA and extensively-resistant strains, such as vancomycin-intermediate&nbsp;<em>S. aureus</em>&nbsp;(VISA), heteroresistant VISA (hVISA), and vancomycin-resistant&nbsp;<em>S. aureus</em>&nbsp;(VRSA).</p>\n<p><strong>Ceftobiprole</strong> is another 5th generation Cephalosporin.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Oral digoxin is being given to a 65-year-old male patient with congestive heart failure as a maintenance dose to gradually digitalize him. A target plasma concentration of 0.70 ng/mL is decided upon. The digoxin clearance for this particular individual is calculated as 60 mL/min. Knowing that the oral bioavailability of digoxin is 70%, what is the dosing rate in this patient?",
    "choices": [
      {
        "id": 1,
        "text": "50 ng/min"
      },
      {
        "id": 2,
        "text": "60 ng/min"
      },
      {
        "id": 3,
        "text": "70 ng/min"
      },
      {
        "id": 4,
        "text": "80 ng/min"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The dosing rate in this patient is\u00a0<strong>60 ng/min.</strong></p>\n<p>The <strong>oral bioavailability of digoxin is 70% (F = 0.7)</strong> and the required target plasma concentration (Cp) is <strong>0.70 ng/mL</strong>. <strong>CL</strong> is the clearance of digoxin which is\u00a060 mL/min.</p>\n<p>Hence, the appropriate dose rate for this patient can be calculated as:</p>\n<p><strong>Dosing rate = Target Cp x CL/F</strong></p>\n<p>= [0.70 ng/mL \u00d7 60 mL/min] \u00f7 [0.7]</p>\n<p>= <strong>60 ng/min</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following statements is false about tramadol?",
    "choices": [
      {
        "id": 1,
        "text": "Maximum recommended daily dose is 400 mg"
      },
      {
        "id": 2,
        "text": "Tramadol-induced respiratory depression is reversed by naloxone"
      },
      {
        "id": 3,
        "text": "For mild-to-moderate pain, morphine is more effective than tramadol"
      },
      {
        "id": 4,
        "text": "Peak action is seen within 2-3 hours and lasts for about 6 hours"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>For the treatment of <strong>mild-to-moderate pain</strong>, <strong>tramadol</strong> is as<strong> effective </strong>as<strong> morphine</strong> or meperidine. However, for the treatment of severe or chronic pain, tramadol is<strong> less effective.</strong></p>\n<p><strong>Tramadol&nbsp;</strong>is a synthetic codeine analog&nbsp;that acts as a <strong>mu-opioid receptor&nbsp;agonist</strong>. It also acts by inhibiting the uptake of norepinephrine and serotonin.&nbsp;The <strong>action peaks</strong> within<strong> 2&ndash;3 hours</strong> of oral dosing. The <strong>duration</strong> of <strong>analgesia</strong> is about <strong>6 hours</strong>.</p>\n<p>The <strong>maximum recommended daily dose</strong> is:</p>\n<ul>\n<li><strong>400 mg</strong> for <strong>adults</strong></li>\n<li>300 mg in patients &gt;75 years old</li>\n<li>200 mg for patients with low creatinine clearance</li>\n</ul>\n<div class=\"page\" title=\"Page 386\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Adverse effects include nausea, vomiting, dizziness, dry mouth, sedation, headache and respiratory depression. Tramadol-induced <strong>respiratory</strong> <strong>depression</strong> is <strong>reversed</strong> by<strong> naloxone</strong>. Tramadol can <strong>exacerbate seizures</strong> in patients with predisposing factors. Tramadol should be avoided in patients taking MAO inhibitors, SSRIs, or other drugs that lower the seizure threshold.</p>\n</div>\n</div>\n</div>\n</div>\n<p><strong>Clinical relevance</strong>: Precipitation of withdrawal necessitates that tramadol is tapered prior to discontinuation.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The lab report of a 35 year old lady who underwent a medical checkup suggests dyslipidemia. She has a past medical history of peptic ulcer disease. Also 2 months back, she had severe pain in her great toe which was cured temporarily by taking NSAIDs. She has been taking statins for past 1 month. Which of the below drugs is absolutely contraindicated in this patient?",
    "choices": [
      {
        "id": 1,
        "text": "Ezetimibe"
      },
      {
        "id": 2,
        "text": "Cholestyramine"
      },
      {
        "id": 3,
        "text": "Evolocumab"
      },
      {
        "id": 4,
        "text": "Niacin"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Niacin</strong> would be <strong>absolutely contraindicated</strong> for the lady presenting with the above clinical history.\u00a0</p>\n<p>Contraindications to niacin are:</p>\n<ul>\n<li>Pregnancy</li>\n<li>Concurrent use with statin - causes myopathy</li>\n<li>History of peptic ulcer disease</li>\n<li>Gout - is a relative contraindication</li>\n</ul>\n<p>Other options:</p>\n<p>Option A- <strong>Ezetimibe</strong> in combination with statin results in further reduction of low density lipoproteins (LDL) cholesterol. However this <strong>combination</strong> should <strong>not be used</strong> in <strong>pregnant</strong> women. Ezetimibe should also not be used along with bile acid sequestrants as they inhibit its absorption.</p>\n<p>Option B- <strong>Cholestyramine</strong> is contraindicated is <strong>severe hypertriglyceridemia</strong> (Note: since the dyslipidemia in the question is not specific, this cannot be the answer).</p>\n<p>Option C- <strong>Evolocumab</strong> is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/Kexin type 9 (PCSK9). It is contraindicated in those with hypersensitivity.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following local anaesthetics is an amide?",
    "choices": [
      {
        "id": 1,
        "text": "Chlorprocaine"
      },
      {
        "id": 2,
        "text": "Benzocaine"
      },
      {
        "id": 3,
        "text": "Prilocaine"
      },
      {
        "id": 4,
        "text": "Procaine"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Prilocaine </strong>is a local anesthetic that is classified as an Amide.</p>\n<p>All the other drugs are classified as esters.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following statements is false about Methacholine?",
    "choices": [
      {
        "id": 1,
        "text": "It is used for diagnosis of bronchial airway hyperreactivity"
      },
      {
        "id": 2,
        "text": "It is more resistant to hydrolysis compared to cholinesterase"
      },
      {
        "id": 3,
        "text": "It has major nicotinic action"
      },
      {
        "id": 4,
        "text": "It has a greater duration of action than ACh"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>Methacholine has a <strong>predominantly muscarinic effect</strong> with only <strong>minor nicotinic</strong> actions, the former manifest most clearly in the cardiovascular system.</p>\n<p>Methacholine is administered by inhalation for the <strong>diagnosis of bronchial airway hyperreactivity</strong> in patients who do not have clinically apparent asthma.</p>\n<p>It is a synthetic choline ester that differs from ACh chiefly in its <strong>greater duration</strong> and selectivity of action. Its action is more prolonged because the added <strong>methyl group increases its resistance</strong> to hydrolysis by cholinesterases.</p>\n<p>&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Coadministration of lenalidomide with which other drug increases the risk for thrombosis?",
    "choices": [
      {
        "id": 1,
        "text": "Antibiotics"
      },
      {
        "id": 2,
        "text": "Barbiturates"
      },
      {
        "id": 3,
        "text": "Glucocorticoids"
      },
      {
        "id": 4,
        "text": "Alcohol"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Lenalidomide and thalidomide</strong> increase the risk for thromboembolic events, including deep vein thrombosis, stroke, and myocardial infarction, which occur with increased frequency in combination with <strong>glucocorticoids and with anthracyclines.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Low dose aspirin should be used with caution in a few patients with co-morbidities. True statement among the following is",
    "choices": [
      {
        "id": 1,
        "text": "In diabetics because it can cause hyperglycemia"
      },
      {
        "id": 2,
        "text": "In children with viral disease because of the risk of acute renal failure"
      },
      {
        "id": 3,
        "text": "In gout because it can increase serum uric acid"
      },
      {
        "id": 4,
        "text": "In pregnancy, because of high risk of teratogenicity"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Aspirin at lower doses (&lt;2 g/day) causes urate retention </strong>and<strong> block the effect of uricosuric drugs</strong>.</p>\n<p>At intermediate doses (2-3 g/day), there is&nbsp;no effect on urate levels.</p>\n<p>Only at high doses (&gt;5 g/day), there is uricosuric effect <strong>but such large doses have poor tolerability.</strong></p>\n<p>Aspirin use is associated with Reye&rsquo;s syndrome which is a rare form of hepatic encephalopathy seen in children having a viral disease (Option B).</p>\n<p><strong>Low dose aspirin</strong> use is not associated with hyperglycemia but<strong> can cause hypoglycemia</strong> in diabetic patients that warrants caution (Option A).</p>\n<p>In pregnancy, the use of aspirin is <strong>associated with low birth weight and perinatal complications</strong> but <strong>not with a high risk of teratogenicity</strong> (Option D).</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The inhibition of hydrochloric acid secretion by omeprazole occurs within an hour, reaches a peak at 2 hours, and plateaus by the 4th day. After how many days will the secretion gradually normalize after stopping the drug?",
    "choices": [
      {
        "id": 1,
        "text": "<24 hours"
      },
      {
        "id": 2,
        "text": "1-2 days"
      },
      {
        "id": 3,
        "text": "3-4 days"
      },
      {
        "id": 4,
        "text": "6-10 days"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The secretion resumes normally in <strong>3-4 days of stopping</strong> the drug when <strong>new proton pumps are synthesized</strong>.</p>\n<p>Omeprazole after absorption enters into the systemic circulation, after which it diffuses into the parietal cells and accumulates in the acidic canaliculi.</p>\n<p>Inside canaliculi, it is activated by proton catalyzed the formation of a tetracyclic sulfenamide that irreversibly inhibits H+/K+ ATPase.</p>\n<p>Inhibition of HCl secretion occurs within 1 hour and reaches a maximum at 2 hrs.</p>\n<p>The inhibition gradually increases over daily dosing and reaches a plateau after 4 days (80-98% inhibition).</p>\n<p>The secretion resumes gradually over 3-4 days of stopping the drug when new proton pumps are synthesized<strong>.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The most common complication of loop diuretic",
    "choices": [
      {
        "id": 1,
        "text": "Hypocalcaemia"
      },
      {
        "id": 2,
        "text": "Hypokalemia"
      },
      {
        "id": 3,
        "text": "Hyperkalemia"
      },
      {
        "id": 4,
        "text": "Hypercalcaemia"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Hypokalemia</strong> is the <strong>most common complication</strong> of loop diuretics.</p>\n<ul>\n<li><strong>Degree of Hypokalemia</strong> depends on the <strong>duration of action of the drug</strong> &ndash; longer acting drugs have higher risk.</li>\n<li>Presents with - weakness, fatigue, muscle cramps; <strong>cardiac arrhythmias</strong> are the <strong>serious complications.</strong></li>\n<li>Hypokalaemia can be <strong>prevented and treated by:</strong>\n<ul>\n<li>High dietary K+ intake</li>\n<li>Supplements of KCl (24&ndash;72 mEq/day)</li>\n<li>Concurrent use of K+ sparing diuretics</li>\n</ul>\n</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is true about ketorolac?",
    "choices": [
      {
        "id": 1,
        "text": "Has potent anti inflammatory activity"
      },
      {
        "id": 2,
        "text": "It's analgesic action is equal to morphine in post-operative pain"
      },
      {
        "id": 3,
        "text": "It is used as a pre anaesthetic medication"
      },
      {
        "id": 4,
        "text": "It interacts with opiod receptors"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>Analgesic action of ketorolac is equal to morphine in post-operative pain</p>\n<p>Ketorolac, an NSAID is an aryl acetic acid derivative with the following properties</p>\n<ul>\n<li>It has <strong>mild anti-inflammatory</strong> action but is a <strong>potent analgesic</strong> (Option A). In<strong> postoperative pain reduction, </strong>the efficacy of <strong>ketorolac is comparable to morphine</strong>. Many studies have concluded that the analgesic action of ketorolac is equivalent to morphine.&nbsp;</li>\n<li>It does not interact with the opioid receptors and is therefore free of the opioid side effects (<strong>Option D</strong>)</li>\n<li>It is mainly used in postoperative pain relief (<strong>Option C</strong>)</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient presents with fever, abdominal pain, and a recent history of diarrhea. He has associated tenderness over the right upper quadrant of the abdomen. Abdominal CT is shown below. Which of the following drugs is indicated for the management of the CT finding?",
    "choices": [
      {
        "id": 1,
        "text": "Metronidazole"
      },
      {
        "id": 2,
        "text": "Iodoquinol"
      },
      {
        "id": 3,
        "text": "Paromomycin"
      },
      {
        "id": 4,
        "text": "Diloxanide furoate"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>The above clinical scenario of a patient presenting with <strong>fever</strong>, <strong>abdominal pain</strong>, a <strong>recent history of diarrhea,</strong> and an <strong>abdominal CT</strong> showing a moderate-sized <strong>abscess in the right liver lobe</strong> is suggestive of an <strong>amebic liver abscess</strong>. It is an <strong>extra-intestinal infection</strong> caused by <strong><em>Entamoeba histolytica</em></strong> and\u00a0<strong>metronidazole</strong> is the <strong>drug of choice</strong> for treating this condition.\u00a0</p>\n<p>Amebic liver abscess <strong>follows intestinal amebiasis</strong>. However, a history of diarrhea may not always be present as most patients remain asymptomatic carriers. In patients presenting with the above symptoms, <strong>stool examination</strong>, <strong>serological tests</strong>, and <strong>radiological imaging</strong> help to confirm the diagnosis.\u00a0</p>\n<p>Metronidazole is\u00a0the <strong>drug of choice</strong> for treating <strong>invasive amebiasis</strong> like an amebic liver abscess. It is a <strong>nitroimidazole</strong> compound and is a highly <strong>active tissue amebicide. </strong><strong>Tinidazole</strong>, which is another longer-acting imidazole, is also highly effective for the management of this condition. Other tissue amebicides include secnidazole, satranidazole and ornidazole.</p>\n<p>Metronidazole is also effective against <strong>other anaerobic</strong> and <strong>microaerophilic</strong> organisms. It is used in the management of <strong>giardiasis</strong>, <strong>trichomoniasis</strong>, anaerobic bacterial infections (e.g., pelvic or abdominal abscesses following surgery), <strong>pseudomembranous enterocolitis, </strong>and <strong><em>Helicobacter pylori</em> gastritis</strong>.</p>\n<p>Adverse effects include <strong>gastrointestinal manifestations</strong> like anorexia, nausea, and a metallic taste. It is known for its ability to produce a <strong>disulfiram-like reaction</strong> when taken with alcohol. Metronidazole can <strong>decrease the renal elimination of lithium</strong> and potentiate its toxicity. It may also cause significant bleeding in patients on <strong>warfarin therapy</strong>.</p>\n<p>Other options:<br /><br /><strong>Iodoquinol </strong>(Option B), <strong>paromomycin </strong>(Option C), and <strong>diloxanide furoate\u00a0</strong>(Option D) are<strong> luminal amebicides</strong>. They are poorly absorbed and thus reach high concentrations in the bowel and are used in the management of <strong>intestinal amebiasis</strong>. They are also indicated for invasive amebiasis. However, <strong>their role is to eradicate cysts</strong> and <strong>prevent further transmission.</strong> They <strong>would not have any direct effect</strong> on the <strong>extraintestinal liver abscess</strong> as seen in this case.</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/2863a47642994f5f876865075adb5f88.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "Maximum incidence of phototoxicity is associated with:",
    "choices": [
      {
        "id": 1,
        "text": "Norfloxacin"
      },
      {
        "id": 2,
        "text": "Sparfloxacin"
      },
      {
        "id": 3,
        "text": "Lomefloxacin"
      },
      {
        "id": 4,
        "text": "Cotrimoxazole"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>Among fluoroquinolones, <strong>Sparfloxacin has maximum incidence of phototoxicity.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Tolerance occurs to all actions of morphine except:",
    "choices": [
      {
        "id": 1,
        "text": "Miotic"
      },
      {
        "id": 2,
        "text": "Analgesic"
      },
      {
        "id": 3,
        "text": "Euphoric"
      },
      {
        "id": 4,
        "text": "All of the above"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>Tolerance develops to most of the effects of morphine <strong>except miosis, constipation and convulsions</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following drugs doesn\u2019t cause hypoglycemia:",
    "choices": [
      {
        "id": 1,
        "text": "Acarbose"
      },
      {
        "id": 2,
        "text": "Insulin"
      },
      {
        "id": 3,
        "text": "Nateglinide"
      },
      {
        "id": 4,
        "text": "Glipizide"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<ul>\n<li><strong>Acarbose</strong> is an <strong>alpha-glucosidase inhibitor</strong>&nbsp;and hence does not cause Hypoglycemia.</li>\n<li>Reduces conversion of starch and disaccharides to monosaccharides.</li>\n<li>Reduces postprandial hyperglycemia.</li>\n<li>Since it<strong> <strong>doesn&rsquo;t enhance the release of insulin, hypoglycemia doesn&rsquo;t occur</strong>.</strong></li>\n</ul>\n<p>NOTE: Metformin also <strong>does not cause hypoglycemia</strong>. Hypoglycemia during biguanide therapy is essentially unknown. These agents are therefore more appropriately termed &ldquo;euglycemic&rdquo; agents.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following antiepileptic drug does not act via inhibition of sodium channels:",
    "choices": [
      {
        "id": 1,
        "text": "Phenytoin"
      },
      {
        "id": 2,
        "text": "Lamotrigine"
      },
      {
        "id": 3,
        "text": "Vigabatrin"
      },
      {
        "id": 4,
        "text": "Topiramate"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Vigabatrin</strong> is a <strong>GABA transaminase inhibitor</strong> and has <strong>no effect on sodium channels</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The drug not acting on tubulin is:",
    "choices": [
      {
        "id": 1,
        "text": "Colchicine"
      },
      {
        "id": 2,
        "text": "Paclitaxel"
      },
      {
        "id": 3,
        "text": "Bleomycin"
      },
      {
        "id": 4,
        "text": "Vincristine"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Bleomycin</strong> is a <strong>glycopeptide antibiotic</strong> acting by <strong>formation of free radicals and causing DNA strand breakage</strong>.</p>\n<p><strong>Microtubule damaging agents</strong> are:</p>\n<ul>\n<li>Vincristine (Oncovin)</li>\n<li>Vinblastine</li>\n<li>Vinorelbine</li>\n<li>Paclitaxel</li>\n<li>Docetaxel</li>\n<li>Estramustine</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following antitubercular drug is bacteriostatic:",
    "choices": [
      {
        "id": 1,
        "text": "Isoniazid"
      },
      {
        "id": 2,
        "text": "Rifampicin"
      },
      {
        "id": 3,
        "text": "Pyrazinamide"
      },
      {
        "id": 4,
        "text": "Ethambutol"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Ethambutol</strong> is the <strong>only bacteriostatic drug</strong> among the first line antitubercular drugs.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following antiglaucoma medications is unsafe in infants?",
    "choices": [
      {
        "id": 1,
        "text": "Timolol"
      },
      {
        "id": 2,
        "text": "Brimonidine"
      },
      {
        "id": 3,
        "text": "Latanoprost"
      },
      {
        "id": 4,
        "text": "Dorzolamide"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The use of <strong>brimonidine </strong>is<strong> unsafe </strong>in infants<strong>. </strong>It is an<strong> alpha-2 agonist</strong>&nbsp;that&nbsp;can cross the blood-brain barrier. This&nbsp;may result in <strong>CNS depression</strong> and<strong> apnoea</strong> in neonates. Therefore it is contraindicated&nbsp;in children less than 2 years.</p>\n<p>&alpha;<sub>2</sub>&nbsp;agonists, through the activation of G-protein coupled receptor activation, inhibit the activity of adenylate cyclase. This reduces cAMP and hence reduces aqueous humor production by ciliary action.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 70-year-old man was administered penicillin intravenously for Anthrax disease. Within 5 minutes, he developed generalized urticaria, swelling of lips, hypotension, and bronchospasm. The 1st choice drug to administer is",
    "choices": [
      {
        "id": 1,
        "text": "Chlorpheniramine injection"
      },
      {
        "id": 2,
        "text": "High dose corticosterone tablet"
      },
      {
        "id": 3,
        "text": "Nebulized salbutamol"
      },
      {
        "id": 4,
        "text": "Epinephrine injection"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>Generalized urticaria, swelling of lips, hypotension, and bronchospasm suggests that the patient is developing <strong>anaphylactic shock.&nbsp;</strong><strong>Epinephrine </strong>injection administered<strong> intramuscularly </strong>is the preferred choice in anaphylactic shock. Epinephrine is a&nbsp;<strong>powerful bronchodilator</strong>&nbsp;and it is a <strong>potent vasopressor</strong>.</p>\n<p>Antihistamines have only an adjuvant role in anaphylactic shock and are not routinely used in emergency cases.&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 40-year-old woman had diabetes mellitus that was not controlled with oral hypoglycemic agents. She was started on short-acting insulin to prevent post-prandial glycemia. Which of the following drug would have been used?",
    "choices": [
      {
        "id": 1,
        "text": "Insulin aspart"
      },
      {
        "id": 2,
        "text": "Insulin glargine"
      },
      {
        "id": 3,
        "text": "Insulin detemir"
      },
      {
        "id": 4,
        "text": "Insulin degludec"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>Among the given options, <strong>insulin aspart</strong> is a <strong>short-acting insulin</strong> that has better control of meal time hyperglycemia and lower rates of postprandial hypoglycemic events.&nbsp;</p>\n<div class=\"page\" title=\"Page 877\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The short-acting insulin analogs are absorbed more rapidly from subcutaneous sites and should be <strong>injected 15 min or less</strong> before a meal. When used to treat glycemia after meals, the short-acting analogs have lower rates of hypoglycemia and improved A1c levels.&nbsp;It has rapid absorption and a shorter duration of action due to instantaneous dissociation into monomers. Short-acting insulin analogs are:</p>\n<ul>\n<li><strong>Insulin lispro</strong> is identical to human insulin except at positions B28 and B29.</li>\n<li><strong>Insulin aspart</strong> is formed by the replacement of proline at B28 with aspartic acid, reducing self-association.</li>\n<li><strong>Insulin glulisine</strong> is formed when glutamic acid replaces lysine at B29 and lysine replaces asparagine at B3.</li>\n</ul>\n<p><strong>Regular insulin</strong> has slow absorption following subcutaneous injection and should be injected 30&ndash;45 min before a meal.&nbsp;</p>\n</div>\n</div>\n</div>\n</div>\n<p>Short-acting insulins are used in the management of diabetes mellitus, diabetic ketoacidosis (regular insulin) and in non-ketotic hyperosmolar hyperglycemic coma.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Initial dose of edrophonium for diagnoisis of myasthenia gravis is_____________",
    "choices": [
      {
        "id": 1,
        "text": "1mg IV"
      },
      {
        "id": 2,
        "text": "1.5mg IV"
      },
      {
        "id": 3,
        "text": "2mg IV"
      },
      {
        "id": 4,
        "text": "10mg IV"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Edrophonium</strong> is used in <strong>Ameliorative test</strong> for diagnosing myasthenia gravis. An initial dose of <strong>2mg</strong> is given as IV push over 15-30sec..</p>\n<ul>\n<li style=\"text-align: left;\">Initially,&nbsp;<strong>2 mg</strong> is administered. If improvements of symptoms do not occur within 45 seconds, an additional 8 mg can be administered.</li>\n<li style=\"text-align: left;\">Improvement of strength unaccompanied by lingual fasciculations is a positive test.</li>\n<li style=\"text-align: left;\">Edrophonium is short-acting because\n<ul>\n<li style=\"text-align: left;\">The binding site of edrophonium to acetylcholine esterase: choline subsite of the active center</li>\n<li style=\"text-align: left;\">No reaction with the enzyme: reversible binding only</li>\n<li style=\"text-align: left;\">Quaternary structure: rapid elimination</li>\n</ul>\n</li>\n</ul>\n<p>Edrophonium in Reversal of Nondepolarizing Neuromuscular Blockers:</p>\n<ul>\n<li>10 mg IV over 30-45 secs</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient presents with seizures, severe abdominal pain, and dark-colored urine. She has a previous history of repeated hospital admission for similar complaints. A diagnosis of acute intermittent porphyria was made after a detailed workup. Which of the following drugs is contraindicated in this patient?",
    "choices": [
      {
        "id": 1,
        "text": "Theophylline"
      },
      {
        "id": 2,
        "text": "Barbiturate"
      },
      {
        "id": 3,
        "text": "Chlorpromazine"
      },
      {
        "id": 4,
        "text": "Benzodiazepine"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The administration of <strong>barbiturates</strong> is <strong>contraindicated</strong> in&nbsp;<strong>acute intermittent porphyria</strong>.</p>\n<p><strong>Acute intermittent porphyria </strong>is a disorder of heme synthesis, characterized by a deficiency of hydroxymethylbilane synthase (HMBS).</p>\n<p>Barbiturates are <strong>enzyme inducers</strong> and they result in the increased synthesis of porphyrins and subsequent <strong>precipitation</strong> of acute intermittent <strong>porphyria.&nbsp;</strong>The biochemical basis for the<strong> worsening </strong>of porphyria by <strong>barbiturates</strong> is<strong> the de-repression/induction </strong>of <strong>ALA synthase.</strong></p>\n<div class=\"ng-scope\">\n<p>Barbiturates are metabolized by<strong> microsomal CYP450, </strong>a <strong>heme-protein oxidase</strong> system found in the liver. In patients with porphyria, barbiturates <strong>precipitate</strong> an attack of <strong>porphyria </strong>by the following mechanism:</p>\n<table style=\"height: 162px; width: 427px;\">\n<tbody>\n<tr>\n<td style=\"width: 417px; text-align: center;\"><strong>&nbsp;</strong>Barbiturates&nbsp;<strong>increase</strong> the synthesis of <strong>CYP450</strong></td>\n</tr>\n<tr>\n<td style=\"width: 417px; text-align: center;\"><strong> &nbsp;</strong>&darr;</td>\n</tr>\n<tr>\n<td style=\"width: 417px; text-align: center;\"><strong>Enhanced consumption</strong> of heme</td>\n</tr>\n<tr>\n<td style=\"width: 417px; text-align: center;\">&darr;</td>\n</tr>\n<tr>\n<td style=\"width: 417px; text-align: center;\">A <strong>decrease</strong> in <strong>heme concentration</strong> in the liver&nbsp;</td>\n</tr>\n<tr>\n<td style=\"width: 417px; text-align: center;\">&darr;</td>\n</tr>\n<tr>\n<td style=\"width: 417px; text-align: center;\"><strong>De-repression/induction of ALAS-1</strong></td>\n</tr>\n<tr>\n<td style=\"width: 417px; text-align: center;\">&darr;</td>\n</tr>\n<tr>\n<td style=\"width: 417px; text-align: center;\"><strong>Increased synthesis</strong> of heme precursors</td>\n</tr>\n<tr>\n<td style=\"width: 417px; text-align: center;\">&darr;</td>\n</tr>\n<tr>\n<td style=\"width: 417px; text-align: center;\">Precipitation of porphyria</td>\n</tr>\n</tbody>\n</table>\n<p><br />Other options:</p>\n<p>Theophylline, chlorpromazine, and benzodiazepine are not contraindicated in&nbsp;acute intermittent porphyria.</p>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The replacement dose of hydrocortisone for chronic adrenal insufficiency is (in mg/day):",
    "choices": [
      {
        "id": 1,
        "text": "10"
      },
      {
        "id": 2,
        "text": "12"
      },
      {
        "id": 3,
        "text": "20"
      },
      {
        "id": 4,
        "text": "5"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The <strong>replacement dose</strong> of hydrocortisone for <strong>chronic adrenal insufficiency</strong> is <strong>2</strong><strong>0 mg/day.</strong></p>\n<p>The treatment of chronic adrenal insufficiency (<strong>not in crisis</strong>) requires glucocorticoid replacement at a dose that replaces the physiologic daily cortisol production. This is achieved by administering an oral replacement dose of 15-25mg Hydrocortisone.\u00a0<br />A <strong>midpoint dose of 20mg</strong> is given in 2-3 divided doses: <strong>10mg + 5mg + 5mg</strong>.\u00a0<br />Half the daily dose should be administered to all patients in the morning. This is to follow the normal circadian rhythm.\u00a0</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following drugs causes flagellate pigmentation?",
    "choices": [
      {
        "id": 1,
        "text": "Bleomycin"
      },
      {
        "id": 2,
        "text": "Doxorubicin"
      },
      {
        "id": 3,
        "text": "Vincristine"
      },
      {
        "id": 4,
        "text": "Minocycline"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><span class=\"TextRun SCXW81824019\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW81824019\"><strong>Flagellate hyperpigmentation/flagellate erythema</strong>&nbsp;</span></span><span class=\"TextRun SCXW81824019\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW81824019\">is</span></span><span class=\"TextRun SCXW81824019\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW81824019\">&nbsp;a characteristic cutaneous reaction to treatment with <strong>b</strong></span></span><strong><span class=\"TextRun Underlined SCXW81824019\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW81824019\">leomycin</span></span></strong><span class=\"TextRun SCXW81824019\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW81824019\">.&nbsp;</span></span></p>\n<p><span class=\"TextRun SCXW81824019\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW81824019\">Clinical features include <strong>multiple linear streaks</strong> (erythematous or hyperpigmented) <strong>at sites of trauma and generalized pruritus</strong>.</span></span></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/378bdd93332c47f1ac9b787f8fc79dccx512x140.PNG"
    ]
  },
  {
    "text": "Carbonic anhydrase inhibitor approved for familial periodic paralysis",
    "choices": [
      {
        "id": 1,
        "text": "Chlorpheniramine"
      },
      {
        "id": 2,
        "text": "Dichlorphenamide"
      },
      {
        "id": 3,
        "text": "Diethylcarbamazine"
      },
      {
        "id": 4,
        "text": "Chlorprocaine"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Dichlorphenamide,</strong> a carbonic anhydrase inhbitor is approved<strong> for familial periodic paralysis.</strong> The mechanism for benefit is still unknown but most probable due to induction of metabolic acidosis.&nbsp;</p>\n<p>Chlorpheiramine is a first generation anti-histaminergic agent (<strong>Option A</strong>).</p>\n<p>Diethylcarbamazine is an antifilarial agent (<strong>Option C</strong>).</p>\n<p>Chloroprocaine is a local anesthetic (<strong>Option D</strong>).</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 40-year-old male comes to the OPD requesting medications to quit smoking. He complains about feeling helpless and hopeless most of the time since years and also reports having suicidal ideations. Which of the following is the drug of choice in this patient?",
    "choices": [
      {
        "id": 1,
        "text": "Nortriptyline"
      },
      {
        "id": 2,
        "text": "Vernaciline"
      },
      {
        "id": 3,
        "text": "Bupropion"
      },
      {
        "id": 4,
        "text": "Rimonabant"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The patient in this case is <strong>well motivated to quit smoking</strong> however the patient is suffering from <strong>depression</strong> and hence the <strong>drug of choice is Bupropion (depressed patient wishing to quit smoking</strong>).</p>\n<ul>\n<li>A sustained-release preparation of the <strong>antidepressant bupropion</strong> improves abstinence rates among smokers and remains a useful option. However, Bupropion decreases the seizure threshold and should be <strong>avoided in patients with a history of seizures.</strong></li>\n<li><strong>Varenicline, a partial agonist at the \u03b14\u03b22 subtype</strong> of the nicotinic acetylcholine receptor, reduces cigarette craving and improves long-term abstinence rates. It has high receptor affinity, thus blocking access to nicotine, so if the treated smoker relapses, there is hardly any reward, and abstinence is more likely to be maintained.</li>\n<li>The nicotine withdrawal syndrome can be alleviated by<strong> nicotine replacement therapy (e.g., nicotine inhaler and nasal spray, nicotine gum or lozenge, or nicotine transdermal patch)</strong>. These methods suppress the symptoms of nicotine withdrawal. However, most resume smoking over the ensuing weeks or months.</li>\n<li>The <strong>cannabinoid CB1 receptor inverse agonist rimonabant </strong>improves abstinence rates and reduces the weight gain seen frequently in ex-smokers. It was found to be linked to<strong> depressive and neurologic symptoms </strong>and is not approved by the FDA.</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following atypical antipsychotics has the highest risk of galactorrhea?",
    "choices": [
      {
        "id": 1,
        "text": "Iloperidone"
      },
      {
        "id": 2,
        "text": "Risperidone"
      },
      {
        "id": 3,
        "text": "Clozapine"
      },
      {
        "id": 4,
        "text": "Aripiprazole"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>Among atypical antipsychotics,<strong>&nbsp;risperidone,</strong><strong>&nbsp;paliperidone </strong>and<strong>&nbsp;amisulpride&nbsp;</strong>have&nbsp;a&nbsp;<strong>higher</strong>&nbsp;<strong>risk of galactorrhoea</strong>.</p>\n<p><strong>Tuberoinfundibular neurons</strong> project <strong>from</strong> the <strong>arcuate</strong> <strong>nucleus</strong> of the hypothalamus <strong>to the anterior pituitary</strong>. <strong>Dopamine</strong> is <strong>delivered</strong> in this region via the hypophyseal vessels. Dopamine <strong>binds to</strong> the <strong>D<sub>2</sub></strong> <strong>receptors</strong> present <strong>on</strong> the <strong>lactotropes</strong> in the <strong>anterior pituitary</strong>, and tonically <strong>inhibits the prolactin secretion</strong> from these cells.&nbsp;</p>\n<p>The <strong>more potent</strong> a D<sub>2</sub> blocking drug is, the <strong>more likely</strong> it is <strong>to cause hyperprolactinemia</strong>. All first-generation antipsychotic drugs cause hyperprolactinemia due to their D<sub>2</sub> blocking&nbsp;properties. Among the <strong>atypical antipsychotics</strong>, <strong>risperidone</strong>, <strong>paliperidone,</strong> and <strong>amisulpride</strong> are associated with <strong>hyperprolactinemia</strong>. Hyperprolactinemia can induce <strong>breast engorgement</strong>, <strong>galactorrhea,</strong> and <strong>infertility</strong> in women, and sexual dysfunction in men.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Longest acting SSRI is",
    "choices": [
      {
        "id": 1,
        "text": "Fluoxetine"
      },
      {
        "id": 2,
        "text": "Fluoxamine"
      },
      {
        "id": 3,
        "text": "Sertraline"
      },
      {
        "id": 4,
        "text": "Citalopram"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Fluoxetine</strong> is the <strong>longest acting SSRI.</strong></p>\n<p>Fluoxetine has <strong>plasma t<sub>1/2</sub> of 48-72 hours.</strong></p>\n<p>It is <strong>metabolized to an active product, norfluoxetine</strong>, which may have <strong>plasma concentrations greater than those of fluoxetine. </strong></p>\n<p>The <strong>elimination half-life of norfluoxetine is about three times longer than fluoxetine (180 hours)</strong> and contributes to the <strong>longest half-life of all the SSRIs. </strong></p>\n<p>As a result, fluoxetine has to be <strong>discontinued 4 weeks or longer before an MAOI can be administered to mitigate the risk of serotonin syndrome.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Following a kidney transplant, a 24-year-old male patient is placed on cyclosporine but after 48 hours complains of serious nausea and diarrhea and has a sudden increase in transaminases. You switch him to tacrolimus but nausea persists and he complains of getting dizzy and has dyspnea. Which of the following immunosuppressive agents would be an alternate drug in this scenario?",
    "choices": [
      {
        "id": 1,
        "text": "Mycophenolate mofetil"
      },
      {
        "id": 2,
        "text": "Etanercept"
      },
      {
        "id": 3,
        "text": "Tocilizumab"
      },
      {
        "id": 4,
        "text": "Basiliximab"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"><strong>Mycophenolate</strong> <strong>mofetil</strong> is the immunosuppressive agent that would be an alternate drug in this scenario indicated as a prophylaxis for transplant rejection</span><strong>.\u00a0</strong></p>\n<p>Mycophenolate mofetil is a prodrug that is rapidly converted to mycophenolic acid. It is a selective, non-competitive, <strong>reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH),</strong> an important enzyme in the de novo pathway of guanine nucleotide synthesis and a suitable alternative for managing transplant rejection in cases where cyclosporine or tacrolimus is not tolerated.\u00a0</p>\n<p><strong>Cyclosporine</strong> is commonly used for <strong>immunosuppression</strong> following <strong>transplantation</strong> to <strong>prevent organ rejection</strong>. However, it can cause side effects such as <strong>nausea, diarrhoea</strong>, and <strong>elevated liver enzymes</strong>. These symptoms are <strong>adverse effects</strong> of cyclosporine rather than indicative of treatment failure.</p>\n<p><strong>Azathioprine</strong> may be used as another alternative, although it is <strong>less commonly preferred</strong> due to its potential for <strong>myelosuppression.</strong></p>\n<p>When a patient experiences i<strong>ntolerable side effects</strong> with <strong>cyclosporine, tacrolimus</strong> is often used as an <strong>alternative</strong>. Tacrolimus, another effective immunosuppressant, can also cause nausea, <strong>dizziness</strong>, and <strong>dyspnea</strong> in some patients.</p>\n<p>Other options:</p>\n<p>Option B:<strong> Etanercept</strong> is a <strong>TNF-\u03b1 antagonist</strong> used in rheumatoid arthiritis and Crohn\u2019s disease.</p>\n<p>Option C: <strong>Tocilizumab</strong> is an <strong>anti-IL-6 antibody</strong> that would be of little benefit following an organ transplant.</p>\n<p>Option D: <strong>Basiliximab</strong> is an interleukin-2 receptor antagonist for activated T lymphocytes that may cause shortness of breath. As the patient has dyspnoea, the administration of basiliximab will further worsen his condition.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "All of the following statements are true about Ertugliflozin, which has been recently approved by the FDA, except",
    "choices": [
      {
        "id": 1,
        "text": "It is indicated for the treatment of type I diabetes mellitus"
      },
      {
        "id": 2,
        "text": "It is a sodium glucose co-transporter 2 (SGLT2) inhibitor"
      },
      {
        "id": 3,
        "text": "It is not recommended in patients with an estimated GFR below 30 mL/minute/1.73 m2"
      },
      {
        "id": 4,
        "text": "Female genital mycotic infections are the most common among all adverse reactions"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<ul>\n<li><strong>Ertugliflozin</strong>\u00a0is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise <strong>to improve glycemic control in adults with type 2 diabetes mellitus.</strong></li>\n<li>It is <strong>not used for the treatment of type 1 diabetes mellitus</strong> or <strong>diabetic ketoacidosis</strong>.</li>\n</ul>\n<p><strong>Dosage and administration:</strong></p>\n<ul>\n<li>The recommended starting dose is <strong>5 mg once daily</strong>, taken in the morning, with or without food.</li>\n<li>The dosage<strong> can be increased to 15 mg once daily</strong> in those tolerating Ertugliflozin and needing additional glycemic control.</li>\n<li>Do not use in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m<sup>2</sup>.</li>\n<li>Initiation and continued use are not recommended in patients with an eGFR persistently between 30 and less than 60 mL/min/1.73 m<sup>2</sup>.</li>\n</ul>\n<p><strong>Mechanism of action:</strong></p>\n<ul>\n<li><strong>SGLT2</strong> is the predominant transporter responsible for <strong>reabsorption of glucose from the glomerular filtrate</strong> back into the circulation.</li>\n<li><strong>Ertugliflozin</strong> is an <strong>inhibitor of SGLT2</strong>.</li>\n<li>By inhibiting SGLT2, Ertugliflozin <strong>reduces renal reabsorption of filtered glucose</strong> and lowers the renal threshold for glucose, and thereby increases urinary<strong>\u00a0glucose excretion.</strong></li>\n</ul>\n<p><strong>Contraindication:</strong></p>\n<ul>\n<li>Severe renal impairment, end-stage renal disease, or dialysis.\u00a0</li>\n<li>History of serious hypersensitivity reaction to Ertugliflozin.</li>\n</ul>\n<p><strong>Adverse reactions:</strong></p>\n<ul>\n<li>The <strong>most common adverse reactions</strong> associated with Ertugliflozin (incidence \u2265 5%) were <strong>female genital mycotic infections.</strong></li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A neurology resident changed the current oral medication of a patient with Alzheimer's disease to a transdermal patch of a cholinesterase inhibitor. What must be the new drug that was prescribed?",
    "choices": [
      {
        "id": 1,
        "text": "Tacrine"
      },
      {
        "id": 2,
        "text": "Donepezil"
      },
      {
        "id": 3,
        "text": "Rivastigmine"
      },
      {
        "id": 4,
        "text": "Galantamine"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Rivastigmine</strong>&nbsp;is a cholinesterase inhibitor that is available as a <strong>transdermal patch</strong> for use in Alzheimer's disease. It can&nbsp;be applied for over 24 hours. Transdermal delivery <strong>reduces the fluctuation</strong> and avoids direct gastric irritation effects associated with oral formulations.&nbsp;</p>\n<p>Option A: Tacrine is an anticholinesterase that is obsolete because of its association with hepatotoxicity.&nbsp;</p>\n<p>Options B and D: Donepezil and galantamine transdermal formulations are under development and <strong>yet to be available</strong> in the market.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is available for intravenous administration for influenza B infections?",
    "choices": [
      {
        "id": 1,
        "text": "Zanamivir"
      },
      {
        "id": 2,
        "text": "Oseltamivir"
      },
      {
        "id": 3,
        "text": "Peramivir"
      },
      {
        "id": 4,
        "text": "None of the above"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Peramivir</strong> is available for<strong> intravenous administration</strong> in <strong>uncomplicated influenza B infections.</strong></p>\n<p>Route of administration of <strong>neuraminidase inhibitors</strong> in influenza</p>\n<p>Zanamivir: Inhalational</p>\n<p>Oseltamivir: Oral</p>\n<p>Peramivir: Intravenous</p>\n<p>Note:</p>\n<p>Oseltamavir and Zanamavir IV formulations are only investigational at present</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient diagnosed with peptic ulcer disease is being treated with sucralfate. Which of the following adverse effects can be seen in the patient?",
    "choices": [
      {
        "id": 1,
        "text": "Vitamin B12 deficiency"
      },
      {
        "id": 2,
        "text": "Increased risk of bone fractures"
      },
      {
        "id": 3,
        "text": "Gastric bezoars"
      },
      {
        "id": 4,
        "text": "Hypergastrinemia"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Gastric bezoar</strong> can be seen in a patient taking sucralfate. Sucralfate produces a <strong>viscous gel that has a \u2018sticky nature\u2019</strong>. The sticky nature may be responsible for gastric bezoars, particularly in those with gastroparesis.</p>\n<div class=\"page\" title=\"Page 919\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Sucralfate is composed of a sulfate of sucrose with Al(OH)<sub>3.\u00a0</sub>It\u00a0undergoes cross-linking to produce a viscous polymer that sticks to epithelial cells and ulcers in acidic environments. It inhibits hydrolysis of the mucosal proteins by pepsin.</p>\n<p>It is used in the prophylaxis of stress ulcers, and in conditions where mucosal ulceration is not responding to acid suppression.</p>\n<p>Adverse effects of sucralfate include constipation and bezoar formation. It may inhibit absorption of other drugs like digoxin, cimetidine, ketoconazole, and fluoroquinolone antibiotics due to the viscous layer formed in the stomach. Hence it should be taken at least 2 hours after administration if these drugs.</p>\n</div>\n</div>\n</div>\n</div>\n<p>The other options:</p>\n<p><strong>Vitamin B12 deficiency </strong>and<strong> increased risk of bone fractures </strong>are side effects of<strong>\u00a0proton pump inhibitors </strong>(PPIs). However, their clinical significance has not been proven yet.\u00a0<strong>Hypergastrinemia</strong> is more commonly seen with<strong> PPIs </strong>than H2 receptor antagonists.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Therapeutic level of lithium (mEq/L) that is indicated for prophylaxis of mania is",
    "choices": [
      {
        "id": 1,
        "text": "1.0-1.5"
      },
      {
        "id": 2,
        "text": "1.5-2.0"
      },
      {
        "id": 3,
        "text": "0.6-1.0"
      },
      {
        "id": 4,
        "text": "<0.6"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>Therapeutic level of lithium that is indicated for <strong>prophylaxis of mania</strong> is\u00a0<strong>0.6-1.0mEq/L</strong></p>\n<p>Target therapeutic levels for lithium in various conditions</p>\n<p><strong>1.0-1.5mEq/L</strong>: Acute mania</p>\n<p><strong>0.6-1.0mEq/L</strong>: Prophylaxis of acute mania</p>\n<p><strong>0.6-1.0mEq/L</strong>: Bipolar disorder</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is an atypical antipsychotic?",
    "choices": [
      {
        "id": 1,
        "text": "Fluphenazine"
      },
      {
        "id": 2,
        "text": "Perphenazine"
      },
      {
        "id": 3,
        "text": "Cariprazine"
      },
      {
        "id": 4,
        "text": "Thioradazine"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Cariprazine</strong> is an <strong>atypical antipsychotic</strong> with <strong>partial agonist activity at D2 receptors and 5-HT2A receptors.</strong></p>\n<p>Fluphenazine, perphenazine and thioridazine are first-generation typical antipsychotics having D2 receptor antagonism activity (options a,b and d).</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following statements accurately depicts the effect of ethyl alcohol on CYP2E1?",
    "choices": [
      {
        "id": 1,
        "text": "Chronic consumption results in inhibition"
      },
      {
        "id": 2,
        "text": "Chronic consumption results in induction"
      },
      {
        "id": 3,
        "text": "Acute consumption results in induction"
      },
      {
        "id": 4,
        "text": "No effect on both acute and chronic consumption"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>Chronic consumption of ethyl alcohol results in the\u00a0<strong>induction of CYP2E1 enzymes</strong> and results in faster metabolism of drugs that are dependent on CYP2E1.</p>\n<p>Acutely, ethyl alcohol can inhibit the action of various metabolizing enzymes including CYP2E1.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "GABA transporter inhibitor among the following is",
    "choices": [
      {
        "id": 1,
        "text": "Vigabatrin"
      },
      {
        "id": 2,
        "text": "Tiagabine"
      },
      {
        "id": 3,
        "text": "Pregabalin"
      },
      {
        "id": 4,
        "text": "Gabapentin"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Tiagabine</strong> acts by <strong>depressing GABA transporter GAT-1</strong> that is involved in the removal of synaptically released GABA.</p>\n<p>Vigabatrin is an inhibitor of GABA transaminase (option a).</p>\n<p>Pregabalin and gabapentin are structurally similar to GABA but do not have any effect on GABA transporter or metabolism (options c and d).</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Sugammadex is a reversal agent for",
    "choices": [
      {
        "id": 1,
        "text": "Succinylcholine"
      },
      {
        "id": 2,
        "text": "Dantrolene"
      },
      {
        "id": 3,
        "text": "Rocuronium"
      },
      {
        "id": 4,
        "text": "All of the above"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Sugammadex</strong> is a novel reversal agent for <strong>rocuronium and vecuronium.</strong></p>\n<p>Sugammadex is a modified gamma-cyclodextran that binds rocuronium and vecuronium tightly and decreases the concentration of free plasma levels.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Incorrect statement about angiotensin II is",
    "choices": [
      {
        "id": 1,
        "text": "Used clinically to increase blood pressure in shock"
      },
      {
        "id": 2,
        "text": "Decreases thirst"
      },
      {
        "id": 3,
        "text": "Stimulates release of ADH"
      },
      {
        "id": 4,
        "text": "Stimulates release of aldosterone"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>Angiotensin II through central action increases ADH secretion and <strong>induces thirst</strong> (option b).</p>\n<p>Angiotensin II causes the release of aldosterone from the adrenal cortex (option d).</p>\n<p>Angiotensin II is recently approved (2017-USFDA) for clinical use to increase blood pressure in patients with septic or other distributive shocks (option a).</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Class 1A antiarrhythmic agents block the following ion channels",
    "choices": [
      {
        "id": 1,
        "text": "Sodium"
      },
      {
        "id": 2,
        "text": "Potassium"
      },
      {
        "id": 3,
        "text": "Both a and b"
      },
      {
        "id": 4,
        "text": "Calcium"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Class 1A</strong> antiarrhythmic agents <strong>block sodium channels</strong> with moderate intensity. It also has an <strong>additional action</strong> of <strong>blockade of potassium channels</strong> that is responsible for <strong>prolonging the action potential duration</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Choose the correct pair matching with the diagram",
    "choices": [
      {
        "id": 1,
        "text": "A: Thiazides B: Carbonic anhydrase inhibitors"
      },
      {
        "id": 2,
        "text": "A: Loop diuretics B: Thiazides"
      },
      {
        "id": 3,
        "text": "A: Thiazides B: Loop diuretics"
      },
      {
        "id": 4,
        "text": "A: Loop diuretics B: Carbonic anhydrase inhibitors"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>A is the loop of Henle; loop diuretics</strong> act on the thick ascending limb of the loop of Henle. <strong>B is proximal convoluted tubule; carbonic anhydrase inhibitors</strong> act on this part.</p>\n<p>\u00a0</p>\n<p>\u00a0</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/b5bf7be9e10e41ccada2362472a803c6.PNG"
    ],
    "explanation_images": []
  },
  {
    "text": "Which of the following is not a TNF alpha inhibitor?",
    "choices": [
      {
        "id": 1,
        "text": "Infliximab"
      },
      {
        "id": 2,
        "text": "Etanercept"
      },
      {
        "id": 3,
        "text": "Anakinra"
      },
      {
        "id": 4,
        "text": "Golimumab"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Anakinra</strong> is a recombinant, non-glycosylated form of <strong>human interleukin 1A</strong>. It is approved for use in <strong>rheumatoid arthritis</strong> and for cryopyrin-associated periodic syndromes (CAPS).</p>\n<p><strong>Infliximab, etanercept, and golimumab</strong> are <strong>TNF alpha inhibitors</strong> (options a, b and d). Adalimumab &amp; Certolizumab are other TNF alpha inhibitors</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following, acts by inhibiting the action of a transporter?",
    "choices": [
      {
        "id": 1,
        "text": "Pilocarpine"
      },
      {
        "id": 2,
        "text": "Probenecid"
      },
      {
        "id": 3,
        "text": "Acetazolamide"
      },
      {
        "id": 4,
        "text": "Vigabatrin"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Probenecid</strong> is a <strong>uricosuric agent</strong> that acts by inhibiting the <strong>organic anion transporter (OATP)</strong> in renal tubules.</p>\n<p><strong>Pilocarpine</strong> is a <strong>muscarinic agonist</strong> (option a).</p>\n<p><strong>Acetazolamide</strong> inhibits <strong>carbonic anhydrase</strong> enzyme (option c).</p>\n<p><strong>Vigabatrin</strong> is a <strong>GABA transaminase inhibitor</strong> (option d).</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Metolazone belongs to the following class of diuretics",
    "choices": [
      {
        "id": 1,
        "text": "Loop diuretics"
      },
      {
        "id": 2,
        "text": "Potassium sparing diuretics"
      },
      {
        "id": 3,
        "text": "Thiazide like diuretics"
      },
      {
        "id": 4,
        "text": "Carbonic anhydrase inhibitors"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Metolazone</strong> is a thiazide-like diuretic.</p>\n<p>Points to note about metolazone:</p>\n<ul>\n<li>Unlike other diuretics, the <strong>antihypertensive and diuretic action</strong> of metolazone is <strong>retained even in severe renal failure (GFR &lt;15 ml/min).</strong></li>\n<li><strong>Additional proximal tubular action</strong> has been observed.</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Mechanism of action of nicorandil in angina is/are",
    "choices": [
      {
        "id": 1,
        "text": "Has a nitrate-like action"
      },
      {
        "id": 2,
        "text": "Agonist at ATP-sensitive potassium channels"
      },
      {
        "id": 3,
        "text": "Both A and B"
      },
      {
        "id": 4,
        "text": "pFOX inhibition"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>Nicorandil has both <strong>nitrate-like</strong> <strong>(c-GMP dependent) properties</strong> and acts as an <strong>agonist of ATP-sensitive potassium channels</strong>.</p>\n<p>Vasodilating action of nicorandil is potentiated by PDE5 inhibitors and only partially blocked by inhibitors of potassium sensitive ATP channels suggesting that both mechanisms is relevant for its action.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Beta-blocker having potassium channel opening action",
    "choices": [
      {
        "id": 1,
        "text": "Carvedilol"
      },
      {
        "id": 2,
        "text": "Carteolol"
      },
      {
        "id": 3,
        "text": "Nebivolol"
      },
      {
        "id": 4,
        "text": "Tilisolol"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Tilisolol</strong> is a third-generation non-selective beta-blocker having an additional action of opening the potassium channels.</p>\n<p>Additional activities of 3<sup>rd</sup> generation beta-blockers:</p>\n<ul>\n<li>\u03b11 adrenergic receptor blockade: labetalol, carvedilol, bucindolol, bevantolol, nipradilol</li>\n<li>Increased production of NO: celiprolol, nebivolol, carteolol, bopindolol, nipradolol</li>\n<li>\u03b22 agonist properties: celiprolol, carteolol, bopindolol</li>\n<li>Ca2+ entry blockade: carvedilol, betaxolol, bevantolol</li>\n<li><strong>Opening of K+ channels: tilisolol</strong></li>\n<li><strong>Antioxidant action: carvedilol</strong></li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The risk of carbamazepine induced Steven Johnson syndrome is increased in the presence of which of the following genes?",
    "choices": [
      {
        "id": 1,
        "text": "HLA-B 1507"
      },
      {
        "id": 2,
        "text": "HLA-B 1502"
      },
      {
        "id": 3,
        "text": "HLA-B 5701"
      },
      {
        "id": 4,
        "text": "HLA-B 2406"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>HLA allele B-1502 </strong>is implicated as a <strong>marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis</strong> in Han Chinese, the USFDA recommends genotyping all Asians for the allele.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The most effective drug in the treatment of loa-loa is?",
    "choices": [
      {
        "id": 1,
        "text": "Ivermectin"
      },
      {
        "id": 2,
        "text": "Chloroquine"
      },
      {
        "id": 3,
        "text": "Diethylcarbamazine (DEC)"
      },
      {
        "id": 4,
        "text": "Pyrantel pamoate"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>DEC</strong> - Diethylcarbamazine is the<strong>&nbsp;drug of choice for the treatment of loiasis</strong>, but it is advisable to start with a small initial dose to diminish host reactions that result from the destruction of microfilariae.</p>\n<p class=\"p1\">Treatment is initiated with test doses of <strong>50 mg</strong> (1 mg/kg in children) daily for 2&ndash;3 days, escalating to maximally tolerated daily doses of <strong>9 mg/kg</strong> in three doses for <strong>2&ndash;3 weeks</strong>.</p>\n<p>Glucocorticoids pretreatment may be administered to ameliorate acute reactions. In rare instances, life-threatening encephalopathy follows the treatment of loiasis, probably due to the inflammatory reaction to dead or dying microfilariae lodged in the cerebral microvasculature.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Ibrutinib is a _______",
    "choices": [
      {
        "id": 1,
        "text": "Tyrosine Kinase inhibitor"
      },
      {
        "id": 2,
        "text": "BCR-ABL Kinase inhibitor"
      },
      {
        "id": 3,
        "text": "Cyclin Dependent Kinase(CDK) inhibitor"
      },
      {
        "id": 4,
        "text": "Janus associated kinase(Jak1) inhibitor"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Ibrutinib</strong> is a <strong>Bruton</strong> <strong>Tyrosine kinase</strong> <strong>inhibitor</strong>. It inhibits malignant B cell proliferation - used in CLL, SLL, Waldenstrom's Macroglobulinemia.</p>\n<p>Imatininib is a BCR- ABL kinase inhibitor.</p>\n<p>Palbociclib is a CDK inhibitor approved for use in metastatic breast carcinoma.</p>\n<div class=\"page\" title=\"Page 1216\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Ruxolitinib is Jak1/2 inhibitor indicated for the treatment of patients with polycythemia vera who have had an inadequate response to hydroxyurea and for the treatment of myelofibrosis.</p>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Mechanism of action of alendronate is _____",
    "choices": [
      {
        "id": 1,
        "text": "Inhibits osteoblasts"
      },
      {
        "id": 2,
        "text": "Increases calcium reabsorption from kidney"
      },
      {
        "id": 3,
        "text": "Stimulates osteoblasts"
      },
      {
        "id": 4,
        "text": "Inhibits osteoclasts"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Alendronate</strong>, a bisphosphonate acts by <strong>direct inhibition of bone resorption.</strong> Bisphosphonates concentrate at sites of active remodeling, remain in the matrix until the bone is remodeled, and then are released in the acid environment of the resorption lacunae and <strong>induce apoptosis in osteoclasts.</strong></p>\n<p>Although bisphosphonates prevent hydroxyapatite dissolution, their <strong>antiresorptive action is due to direct inhibitory effects on osteoclasts.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Beta blockers belong to which class of antiarrhythmic drugs",
    "choices": [
      {
        "id": 1,
        "text": "I"
      },
      {
        "id": 2,
        "text": "II"
      },
      {
        "id": 3,
        "text": "III"
      },
      {
        "id": 4,
        "text": "IV"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>According to <strong>Vaughan Williams and Singh&rsquo;s classification of Antiarrhythmic drugs beta blockers are included in type II.</strong></p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;<strong>Class I</strong></td>\n<td>\n<p><strong>Membrane stabilizing agents (Na+ channel blockers)</strong></p>\n<ul>\n<li>Moderately decrease dv/dt of 0 phase</li>\n<li>Little decrease in dv/dt of 0 phase</li>\n<li>Marked decrease in dv/dt of 0 phase&nbsp;</li>\n</ul>\n</td>\n<td>&nbsp;\n<ul>\n<li><strong>Quinidine, Procainamide, Disopyramide</strong></li>\n<li><strong>Lidocaine, Mexiletine</strong></li>\n<li><strong>Propafenone, Flecainide</strong>&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Class II</strong></td>\n<td><strong>Anti-adrenergic agents </strong><strong>(&beta; blockers)</strong></td>\n<td>Propranolol, Esmolol, Sotalol (also class III)&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Class III</strong></td>\n<td><strong>Agents widening AP&nbsp;</strong>(prolong repolarization and ERP) &nbsp;</td>\n<td>Amiodarone, Dronedarone, Dofetilide, Ibutilide</td>\n</tr>\n<tr>\n<td><strong>Class IV</strong></td>\n<td><strong>Calcium channel blockers</strong></td>\n<td>Verapamil, Diltiazem</td>\n</tr>\n<tr>\n<td><strong>Class V</strong></td>\n<td><strong>Miscellaneous</strong></td>\n<td>Digoxin, adenosine, magnesium, atropine and potassium.&nbsp;</td>\n</tr>\n</tbody>\n</table>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Orexin receptor antagonist indicated for insomnia is",
    "choices": [
      {
        "id": 1,
        "text": "Aprepitant"
      },
      {
        "id": 2,
        "text": "Rolaprepitant"
      },
      {
        "id": 3,
        "text": "Suvorexant"
      },
      {
        "id": 4,
        "text": "Netupitant"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Suvorexant</strong> is the <strong>orexin receptor antagonist</strong> that is approved for <strong>use in insomnia</strong>. <strong>Orexins promote wakefulness</strong> and antagonists of orexin receptor induces sleep.</p>\n<p>Aprepitant, rolaprepitant and netupitant are NK1 receptor antagonist used as antiemetics (options a, b and d).</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Mechanism of action of the antidiarrheal agent racecadotril is",
    "choices": [
      {
        "id": 1,
        "text": "5HT4 receptor agonism"
      },
      {
        "id": 2,
        "text": "5HT3 receptor antagonism"
      },
      {
        "id": 3,
        "text": "Inhibition of peripheral enkephalinase"
      },
      {
        "id": 4,
        "text": "Opioid delta receptor antagonism"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>Racecadotril is a <strong>peripheral enkephalinase inhibitor.</strong></p>\n<p>Enkephalins are delta-opioid receptor agonists that decrease secretions. Racecadotril acts as an antisecretory agent by <strong>increasing enkephalin levels.</strong> It has minimal/no effect on motility.</p>\n<p>Racecadotril is indicated for <strong>symptomatic treatment of diarrhea in infants and children</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Beta-lactamase inhibitor that does not cause suicidal inhibition of beta-lactamase is",
    "choices": [
      {
        "id": 1,
        "text": "Clavulanic acid"
      },
      {
        "id": 2,
        "text": "Avibactam"
      },
      {
        "id": 3,
        "text": "Tazobactam"
      },
      {
        "id": 4,
        "text": "Sulbactam"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Avibactam</strong> is a <strong>newer non-beta lactam beta-lactamase inhibitor</strong>. It is a non-suicidal inhibitor. Causes <strong>reversible acylation of beta-lactamase targets</strong>. Has a <strong>broader spectrum</strong> of action than suicidal inhibitors. <strong>Vaborbactam</strong> is another non-suicidal inhibitor.</p>\n<p>Suicidal inhibitors</p>\n<ul>\n<li>Clavulanic acid</li>\n<li>Tazobactam</li>\n<li>Sulbactam</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "All phase II biotransformation reactions involve non-micorsomal enzymes except",
    "choices": [
      {
        "id": 1,
        "text": "Methylation"
      },
      {
        "id": 2,
        "text": "Acetylation"
      },
      {
        "id": 3,
        "text": "Sulfation"
      },
      {
        "id": 4,
        "text": "Glucuronidation"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Glucuronidation</strong> is the only phase II biotransformation reaction that involves microsomal enzymes.</p>\n<p>All the other phase II biotransformation reactions involve non-micorsomal enzymes (options a, b and c).</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "True regarding liraglutide is _____",
    "choices": [
      {
        "id": 1,
        "text": "PPAR- gamma agonist"
      },
      {
        "id": 2,
        "text": "GLP- 1 receptor agonist"
      },
      {
        "id": 3,
        "text": "Amyloid polypeptide"
      },
      {
        "id": 4,
        "text": "DPP- IV inhibitor"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Liraglutide</strong> is a&nbsp;<strong>GLP- 1 receptor agonist.</strong></p>\n<p>Liraglutide is a soluble fatty acid-acylated GLP-1 analog. The half-life is approximately 12 hours, permitting once-daily dosing. It is approved in patients with type 2 diabetes who achieve inadequate control with diet and exercise and are receiving concurrent treatment with metformin, sulfonylureas, or thiazolidinediones.</p>\n<p>It reduces post-meal hyperglycemia by</p>\n<ul>\n<li>Increasing glucose mediated insulin release</li>\n<li>Lowering glucagon levels</li>\n<li>Slowing gastric emptying</li>\n<li>Decreasing appetite</li>\n</ul>\n<p>It is used in type 2 DM and is the<strong> only GLP-1 receptor agonist used in obesity.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Drug of choice for actinomycosis is:",
    "choices": [
      {
        "id": 1,
        "text": "Penicillin G"
      },
      {
        "id": 2,
        "text": "Ceftriaxone"
      },
      {
        "id": 3,
        "text": "Vancomycin"
      },
      {
        "id": 4,
        "text": "Linezolid"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Penicillin G</strong> is the <strong>agent of choice</strong> for the treatment of all forms of <strong>actinomycosis.</strong></p>\n<p>The dose should be <strong>18-24 million&nbsp;units of penicillin G intravenously</strong> per day <strong>for 6 weeks</strong>. Some physicians continue therapy for 2-3 months with oral penicillin V (500 mg four times daily). Surgical drainage or excision of the lesion may be necessary before a cure is accomplished.</p>\n<p>Alternatively, treatment can also be done with<strong> tetracyclines</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following drugs causes capillary leak syndrome?",
    "choices": [
      {
        "id": 1,
        "text": "Granulocyte-colony stimulating factor"
      },
      {
        "id": 2,
        "text": "Filgrastim"
      },
      {
        "id": 3,
        "text": "Pegfilgrastim"
      },
      {
        "id": 4,
        "text": "Granulocyte-macrophage colony-stimulating factor"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>Granulocyte-macrophage colony-stimulating factor(<strong>GM CSF)</strong> is known to cause <strong>capillary leak syndrome</strong>.</p>\n<p>With prolonged administration, a few patients may develop a capillary leak syndrome, with peripheral edema and pleural and pericardial effusions.</p>\n<p>Other drugs causing capillary leak syndrome:</p>\n<ul>\n<li>IL 2</li>\n<li>IL 4</li>\n<li>Clofarabine</li>\n<li>Denileukin diftitox</li>\n<li>Gemcitabine</li>\n</ul>\n<p>Other options: All of them are Granulocyte-colony stimulating factor analogues and do not cause capillary leak syndrome.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The recent drug approved for the treatment of dry mouth associated with Sjogren\u2019s syndrome is _____",
    "choices": [
      {
        "id": 1,
        "text": "Cevimeline"
      },
      {
        "id": 2,
        "text": "Rivastigmine"
      },
      {
        "id": 3,
        "text": "Donepezil"
      },
      {
        "id": 4,
        "text": "Bethanechol"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Cevimeline</strong>, a quinuclidine derivative of acetylcholine, is a newer <strong>direct-acting muscarinic agonist</strong> used for the<strong> treatment of dry mouth</strong> associated with Sjogren\u2019s syndrome or caused by radiation damage of the salivary glands.</p>\n<p>It is a synthetic <strong>M<sub>3 </sub></strong>selective cholinomimetic drug.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following statements is not true about biotransformation?",
    "choices": [
      {
        "id": 1,
        "text": "Phase I reactions unmask a functional group"
      },
      {
        "id": 2,
        "text": "Phase II reactions may precede phase I reactions"
      },
      {
        "id": 3,
        "text": "Biotransformation of drugs occurs primarily in the liver"
      },
      {
        "id": 4,
        "text": "Flavin containing monooxygenases are a part of phase 2 enzymes"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Flavin containing monooxygenases (FMO) </strong>are a part of Phase 1 oxidation reactions. Others are carried out by <strong>Cytochrome P450s</strong>, , aand <strong>Epoxide hydrolases(EH)</strong>.</p>\n<p><strong>&nbsp;</strong>Phase I reactions usually convert the parent drug to a more polar metabolite by introducing or <strong>unmasking/ adding a functional group</strong> such as &ndash;OH, &ndash;COOH, &ndash;SH, &ndash;O&ndash;, or NH2. Reactions carried out by phase 1 enzymes usually lead to the <strong>inactivation of a drug</strong>/activation of the drug.</p>\n<p>Majority of the drugs undergo these biotransformation reactions in a<strong> sequential manner. </strong>However, rarely<strong> Phase II reactions may precede phase I </strong>reaction.</p>\n<p>The biotransformation of drugs occurs primarily in the <strong>liver</strong>. Other organs with significant drug-metabolizing capacity include the <strong>GI tract, kidneys, and lungs</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "What instruction do you give to a mother who is lactating for drug use?",
    "choices": [
      {
        "id": 1,
        "text": "No advice as most of drug are not present in breast milk"
      },
      {
        "id": 2,
        "text": "Give longer half-life drugs"
      },
      {
        "id": 3,
        "text": "Tell the mother to feed when it is least efficacious"
      },
      {
        "id": 4,
        "text": "To feed just before the next dose, when the plasma concentration of the drug would be the least"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>Ideally, the mother should feed just before the next dose, when the plasma concentration of the drug would be the least.</p>\n<ul>\n<li>The drugs are present in breast milk in variable amount but <strong>lesser than in plasma</strong> of mother.</li>\n<li>Breastfeeding is advised at least&nbsp;<strong>3-4 hours after drug intake</strong> so that plasma concentration is lesser and hence the concentration in the breast milk is also less.</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Calculate the therapeutic index of a drug whose dose-response curves are plotted as shown below:",
    "choices": [
      {
        "id": 1,
        "text": "1"
      },
      {
        "id": 2,
        "text": "2"
      },
      {
        "id": 3,
        "text": "4"
      },
      {
        "id": 4,
        "text": "8"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The <strong>therapeutic index</strong> is <strong>4</strong>.</p>\n<p>In the above graph,</p>\n<p>Median lethal dose (LD50) = 400</p>\n<p>Median effective dose (ED50) = 100</p>\n<p><strong>Therapeutic index (TI)</strong> =<strong>\u00a0LD50/ED50.</strong></p>\n<p>Hence,</p>\n<p>Therapeutic index (TI ) = 400/100 = 4</p>\n<p>Clinically, the therapeutic range bound by the dose that produces the minimal therapeutic effect and the dose that produces the maximal acceptable adverse effect is more relevant.</p>\n<p>\u00a0</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/622c455438be4ab480ed5ee698509c1f.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "The package description of a drug states that 500mg of paracetamol is present in each unit of the tablet formulation, but in reality, each unit contains only 200mg. What is the terminology used to refer to these kinds of drugs?",
    "choices": [
      {
        "id": 1,
        "text": "Misbranded drug"
      },
      {
        "id": 2,
        "text": "Adulterated drugs"
      },
      {
        "id": 3,
        "text": "Spurious drugs"
      },
      {
        "id": 4,
        "text": "Counterfeit drugs"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>A drug stating that 500mg of paracetamol is present in each tablet, but contains only 200mg is a <strong>misbranded drug</strong>, according to the CDSCO (Central drugs standard control organization).</p>\n<p>The drug and cosmetics act initially passed in 1940 and amended in 2016 provides a definition of&nbsp;<strong>misbranded</strong>, <strong>spurious</strong>, and <strong>adulterated</strong> drugs.</p>\n<p>A drug is considered&nbsp;<strong>misbranded</strong> if it fulfills any of the following three conditions:</p>\n<ul>\n<li>If the appearance of the drug has been altered to conceal physical damage or make it appear of greater therapeutic value than it actually is (or)</li>\n<li>If it is not labeled in the prescribed manner (or)</li>\n<li>If the label or container of the drug makes a false or misleading claim about the drug. In this case, the packet states that there is 500 mg of paracetamol present as opposed to the 200 mg that is actually present.</li>\n</ul>\n<p>A drug is considered&nbsp;<strong>spurious</strong> if it fulfills the following conditions:</p>\n<ul>\n<li>If the drug is imported under a name that belongs to another drug (or)</li>\n<li>If the drug is an imitation of another drug with the intent to deceive (or)</li>\n<li>If the label depicts a manufacturer that is either fictitious or a real company with no ties to the product (or)</li>\n<li>If it has been substituted wholly or in part by another drug or substance.</li>\n</ul>\n<p>A drug is considered <strong>adulterated</strong> if it fulfills the following conditions:</p>\n<ul>\n<li>If it consists wholly or in part of any filthy, putrid, poisonous, or decomposed substance (or)</li>\n<li>If it has been manufactured under unsanitary conditions (or)</li>\n<li>If it bears a coloring other than the one prescribed (or)</li>\n<li>If it has been mixed with any substance that may reduce its quality or strength.</li>\n</ul>\n<p>*Note: The term counterfeit drugs is a broad term and is used by the WHO. This may also be conceived to include misbranded, spurious, or adulterated drugs. However, the term misbranded drugs would be a more appropriate answer here since it is likely that the reference used is from CDSCO.&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The loading dose of a drug is governed primarily by:",
    "choices": [
      {
        "id": 1,
        "text": "Clearance"
      },
      {
        "id": 2,
        "text": "Volume of distribution"
      },
      {
        "id": 3,
        "text": "Plasma half life"
      },
      {
        "id": 4,
        "text": "Bioavailability"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The <strong>volume of distribution</strong> of the drug <strong>determines</strong> the<strong> loading dose</strong> of the drug.</p>\n<p>Loading Dose = Vol. of distribution x Desired steady state plasma concentration.</p>\n<p>When the time to reach a steady-state is long, as it is for <strong>drugs</strong> with <strong>long half-lives,</strong> it may be desirable to <strong>administer</strong> a <strong>loading dose</strong> that promptly raises the concentration of drug in plasma to the target concentration.</p>\n<p>Option A:<strong>&nbsp;</strong>Clearance is used to determine the maintenance dose.&nbsp;</p>\n<p>Maintenance dose = Clearance x&nbsp;Desired Steady-state plasma concentration.</p>\n<p>Options C and D: Plasma <strong>half-life</strong> primarily <strong>determines</strong> the <strong>frequency</strong> of dosing, while <strong>bioavailability</strong> <strong>determines</strong> the <strong>route</strong> of administration.&nbsp;Though bioavailability may affect the dose necessary, it will not be the primary factor considered during the calculation of the loading dose.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "What is the drug of choice for scrub typhus during pregnancy and otherwise respectively?",
    "choices": [
      {
        "id": 1,
        "text": "Chloramphenicol, doxycycline"
      },
      {
        "id": 2,
        "text": "Doxycycline, doxycycline"
      },
      {
        "id": 3,
        "text": "Doxycycline, azithromycin"
      },
      {
        "id": 4,
        "text": "Azithromycin, doxycycline"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>The drug of choice for a case of&nbsp;<strong>scrub typhus</strong> during <strong>pregnancy</strong>&nbsp;is <strong>azithromycin.&nbsp;</strong>For other patients the drug of choice is&nbsp;<strong>doxycycline</strong>.</p>\n<p>An alternative treatment option in pregnant women and patients allergic to doxycycline is chloramphenicol.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following drugs should be sold only on prescription from a registered medical practitioner?",
    "choices": [
      {
        "id": 1,
        "text": "Schedule M drugs"
      },
      {
        "id": 2,
        "text": "Schedule H drugs"
      },
      {
        "id": 3,
        "text": "Schedule J drugs"
      },
      {
        "id": 4,
        "text": "Schedule X drugs"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Schedule H drugs</strong> should be sold only if the prescription is from a registered medical practitioner (RMP).&nbsp;</p>\n<p>Important schedules under the &ldquo;drugs and cosmetics act&rdquo;:<strong>&nbsp;</strong></p>\n<ul>\n<li>C and C1: Biological&nbsp;and special products</li>\n<li>F and F1: Bacterial vaccines</li>\n<li>G: Drugs that must be labelled with the word &ldquo;caution&rdquo; should not be taken without medical supervision</li>\n<li>J: List of diseases and ailments which a drug may not claim to prevent or cure</li>\n<li>M: Good Manufacturing Practices (GMP)</li>\n<li>P: Expiry period of drug formulations</li>\n<li>W: Drugs marketed under generic name only</li>\n<li>X: Psychotropic drugs requiring a special license for manufacture and sale</li>\n<li>Y: Requirements and guidelines on clinical trials, import, and manufacture of new drugs.</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following shows a U-shaped dose-response curve?",
    "choices": [
      {
        "id": 1,
        "text": "Vitamins"
      },
      {
        "id": 2,
        "text": "Anti-cancer drugs"
      },
      {
        "id": 3,
        "text": "Steroids"
      },
      {
        "id": 4,
        "text": "Chelators"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Vitamins</strong>\u00a0and <strong>essential metals</strong> show a <strong>U-shaped dose-response curve</strong>.</p>\n<div class=\"page\" title=\"Page 74\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>At a\u00a0<strong>low dose,</strong> adverse effects are observed because there is a <strong>deficiency</strong> of these nutrients to maintain homeostasis. As <strong>dose increases, homeostasis</strong> is achieved, and the bottom of the U-shaped dose-response curve is reached. As the <strong>dose increases</strong> to surpass the amount required to maintain homeostasis, <strong>toxicity</strong> can ensue.</p>\n<p>Thus, <strong>adverse effects</strong> are seen at both <strong>low</strong> and<strong> high doses.\u00a0</strong></p>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/cbb79628483a49e5bce96265d68a0673x1280x1154.JPEG",
      "https://dhmbxeygs57ff.cloudfront.net/uploads/e0db32ffbadd42dd9c69b75a9398ff60x1280x1420.JPEG",
      "https://dhmbxeygs57ff.cloudfront.net/uploads/23699bc3b29d46ed9c13c1f6a2abef2cx1280x1282.JPEG"
    ]
  }
];
        let quizName = 'Pharmacology Test  Ii';
        const quizFilename = 'pharmacology-test-ii-dfca44bd.html';
        let hierarchy = ["Marrow", "NEET PG Test Series Subject Wise", "Year 2019 - 20"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        // --- NEW: History Management ---
        function saveProgress() {
            if (isQuizCompleted) return; // Don't save after completion
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            userHistory[quizFilename] = {
                questionStates,
                stats,
                currentQuestionIndex,
                currentMode,
                status: 'incomplete',
                lastSeen: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }

        function loadProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const savedState = userHistory[quizFilename];
            if (savedState) {
                questionStates = savedState.questionStates;
                stats = savedState.stats;
                currentQuestionIndex = savedState.currentQuestionIndex;
                currentMode = savedState.currentMode;
                console.log('Progress loaded.');
                return true;
            }
            return false;
        }

        function clearProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            if(userHistory[quizFilename]) {
                delete userHistory[quizFilename];
                localStorage.setItem('userHistory', JSON.stringify(userHistory));
                console.log('Previous progress cleared.');
            }
        }

        function markQuizAsCompleted() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const totalQuestions = questionsData.length;
            const correct = stats.correctAnswers || 0;
            
            userHistory[quizFilename] = {
                score: correct,
                total: totalQuestions,
                status: 'completed',
                completedOn: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }
        // --- End of History Management ---

        const urlParams = new URLSearchParams(window.location.search);
        const startAt = parseInt(urlParams.get('startAt'));
        const resume = urlParams.get('resume') === 'true';

        function goBack() {
            if (!isQuizCompleted) saveProgress(); // Save progress before leaving
            window.location.href = document.referrer || 'index.html';
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            if (!isNaN(startAt) && startAt >= 0 && startAt < questionsData.length) {
                currentQuestionIndex = startAt;
            }

            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                processAnswer();
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
            saveProgress(); // NEW: Save on answer selection
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            showSolution();
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            stats.correctAnswers = correct; // Update global stats
            stats.incorrectAnswers = incorrect;
            markQuizAsCompleted(); // NEW: Mark quiz as complete in history
            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                clearProgress(); // NEW: Clear history on retake
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                        saveProgress();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (resume) {
                if (loadProgress()) {
                    document.getElementById('modeModal').style.display = 'none';
                    initializeQuiz(); // Resume directly into the saved mode and state
                } else {
                    // If resume fails (e.g., cleared history), start fresh
                    clearProgress();
                    document.getElementById('modeModal').style.display = 'flex';
                }
             } else if (!window.location.pathname.endsWith('custom_quiz.html')) {
                clearProgress(); // Clear old progress if not resuming
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>